Leger hails 'step forward' with Medichecks deal
A medical firm has been bought by a national operator.
Leger Clinic is now part of blood test provider Medichecks Group.
Bosses say the deal for the Doncaster-founded testosterone replacement therapy provider marks “a major step forward… in making treatment more accessible and affordable for men across the UK”.
Dr Douglas Savage, who launched Leger Clinic in the late 1980s, said: “Testosterone deficiency is a real issue.
“Patients tell us they’ve lost their get-up-and-go, they’re miserable and their partners are noticing it too.
“I’ve seen first-hand how therapy can transform men’s lives.
“It’s not just about increasing testosterone – it’s about giving men back their energy, confidence and drive.
“By joining Medichecks, we can make monitoring simpler, more affordable and ensure men get the care they need without unnecessary barriers.”
Helen Marsden, co-founder of Medichecks, which has clinics across the UK, added: “Acquiring Leger means we’re ensuring more men can benefit from expert treatment.
“We want men to take control of their health and feel their best again.”
Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →
Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular Yorkshire & The Humber morning email for free.
The true value of HR in an AI-driven working world
What new business rates guidance means for pubs
Business success starts with people investment
It's time to confront the digital poverty crisis
Why a business exit is no longer all or nothing
Culture is the foundation for sustainable growth
Business must help young people take root in work
Purposeful procurement for long-term growth
Time to rethink outdated views on apprenticeships
The scale-ups rocketing through our fast world
Care about the experience, not just the outcome
The rise of an alternative investor model